Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.

MLA

Georgy, J. T., et al. “Pathological Response and Clinical Outcomes in Operable Triple-Negative Breast Cancer with Cisplatin Added to Standard Neoadjuvant Chemotherapy.” Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti, vol. 34, no. 1, Winter 2021, pp. 49–55. EBSCOhost, https://doi.org/10.48095/ccko202149.

APA

Georgy, J. T., Singh, A., John, A. O., Joel, A., Andrews, A. G., Thumaty, D. B., Rebekah, G., Sigamani, E., Chandramohan, J., Manipadam, M. T., Cherian, A. J., Abraham, D. T., Paul, M. J., Balakrishnan, R., Backianathan, S., & Chacko, R. T. (2021). Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy. Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti, 34(1), 49–55. https://doi.org/10.48095/ccko202149

Chicago

Georgy, J T, A Singh, A O John, A Joel, A G Andrews, D B Thumaty, G Rebekah, et al. 2021. “Pathological Response and Clinical Outcomes in Operable Triple-Negative Breast Cancer with Cisplatin Added to Standard Neoadjuvant Chemotherapy.” Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti 34 (1): 49–55. doi:10.48095/ccko202149.